These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11112092)

  • 1. A double-site absorption model fits to pharmacokinetic data of repaglinide in man.
    Liu XD; Ji HF; Xie L; Yan MQ; Zhang L; Huang X
    Eur J Drug Metab Pharmacokinet; 2000; 25(2):115-9. PubMed ID: 11112092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man].
    Liu XD; Xie L; Wang J; Zhou YS; Wang Z; Liu GQ
    Yao Xue Xue Bao; 1996; 31(10):737-41. PubMed ID: 9863240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
    van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
    Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
    Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm.
    Ruzilawati AB; Mohd Suhaimi AW; Gan SH
    J Clin Pharm Ther; 2010 Feb; 35(1):105-12. PubMed ID: 20175819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
    Hatorp V; Huang WC; Strange P
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide pharmacokinetics in healthy young adult and elderly subjects.
    Hatorp V; Huang WC; Strange P
    Clin Ther; 1999 Apr; 21(4):702-10. PubMed ID: 10363735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies.
    Ruzilawati AB; Wahab MS; Imran A; Ismail Z; Gan SH
    J Pharm Biomed Anal; 2007 Apr; 43(5):1831-5. PubMed ID: 17240100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
    Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
    Hatorp V
    Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
    Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of repaglinide in subjects with renal impairment.
    Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
    Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
    Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
    Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
    Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.